Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

About the PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.
Aims & ObjectivesMission StatementEditorial BoardPartnership & OutreachForthcoming Meetings
What will members gain?

New Approaches to PCSK9 inhibition

Prof Derick Raal (University of Witwatersrand, Johannesburg, South Africa) discusses what’s in the pipeline for PCSK9 inhibition beyond the monoclonal antibodies
Read the report

Video: What's in the PCSK9 pipeline?
Watch the video

Hot Topics

Adverse effects of long-term statin therapy: New statement from the EAS Consensus Panel

Clinical trials have clearly proven the efficacy and short-term safety of statin treatment. But, with people taking these medications lifelong, are there any adverse effects to consider in the longer-term? This new statement weighs the evidence versus the perception of risk.

Read the report

Video: EAS Consensus Panel: Statins do not impair cognitive function
Watch the video

Report: Neurocognitive effects and PCSK9 inhibition
Read the report

From the Editors

PCSK9 Monoclonal Antibody Therapy in Patients with Diabetes: Where We Are and Future NeedsPCSK9 Monoclonal Antibody Therapy in Patients with Diabetes: Where We Are and Future Needs

Prof Nathan D. Wong, Heart Disease Prevention Program, University of California, Irvine, USA

PCSK9 monoclonal antibody therapy has been shown to be effective in patients with diabetes. The next priority is to better define those primary prevention patients who would benefit most from treatment.

Read the article

FOURIER: evolocumab in diabetes patients

Read the report

ODYSSEY DM-DYSLIPIDEMIA with alirocumab

Read the report

Meet our Editorial Board

View all our Editorial Board Prof John ChapmanResearch Professor at the University of Pierre and Marie Curie Prof Henry GinsbergDirector, Irving Institute for Clinical and Translational Research Dr Michel FarnierClinician based at Point Medical, Dijon, France Prof Frederick RaalDirector, Carbohydrate & Lipid Metabolism Research Unit Prof Anthony WierzbickiConsultant in Metabolic Medicine/Chemical Pathology